Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 39Carcinoma, Renal Cell 28Carcinoma, Hepatocellular 18Neoplasm Metastasis 16Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Lung Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Esophageal Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Kidney Neoplasms 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

Injections 12pembrolizumab 7toripalimab 5tislelizumab 5Oxaliplatin 3Gemcitabine 3Cisplatin 3Carboplatin 3trastuzumab deruxtecan 2spartalizumab 2lenvatinib 2atezolizumab 2Paclitaxel 2Nivolumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2zimberelimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1fludarabine phosphate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumor × Nivolumab × Clear all
NCT05901285 2026-05-14

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

Vaxiion Therapeutics

Phase 1 Recruiting
48 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Inimmune Corporation

Phase 1 Recruiting
50 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡